Previous 10 | Next 10 |
home / stock / eprx:cc / eprx:cc news
Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus Canada NewsWire VICTORIA, BC , Jan. 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) today announced that it has filed and obtained a r...
Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trial Canada NewsWire Initial low dose presents early efficacy signals Second cohort now fully dosed at twice the initial dose Further results to be disclosed in Q1 2024 VICTORIA, B...
Eupraxia Pharmaceuticals Announces Clinical and Corporate Update Canada NewsWire EP-104IAR and EP-104GI continuing to advance clinically & remain on track Corporate initiatives ongoing to position EP-104IAR and EP-104GI for successful outcomes Company provides mile...
Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results Canada NewsWire VICTORIA, BC , Nov. 14, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovat...
Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology Canada NewsWire Abstract covering Phase 2 osteoarthritis trial results accepted as a late-breaking submission VICTORIA, BC , Nov. 1, 2023 /CNW/ - Euprax...
Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitis Canada NewsWire Preliminary data from the first cohort demonstrates that EP-104GI was well tolerated with no drug-related adverse events reported ...
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference Canada NewsWire VICTORIA, BC , Sept. 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnolo...
Eupraxia Pharmaceuticals Announces Change of Auditor Canada NewsWire /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VICTORIA, BC , Sept. 7, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: ...
Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023 Canada NewsWire VICTORIA, BC , Sept. 6, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative d...
Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125 Canada NewsWire /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ VICTORIA, BC , Aug. 18, 2023 /CNW/ - Eupraxi...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Inc. Company Name:
EPRX:CC Stock Symbol:
TSXC Market:
Eupraxia Pharmaceuticals Inc. Website:
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC , July 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnolo...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control an...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC , June 6, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a cli...